23ANDME HOLDING CO. - COMMON STOCK

23andMe Announces Poster Presentations on 23ME-00610, an Investigational Antibody Targeting CD200R1, at The Society for Immunotherapy of Cancer’s (SITC) 2023 Annual Meeting

27 Sep 2023 16:05:00 By Nasdaq GlobeNewswire

23andMe and Sickle Cell 101 Collaborate to Expand Sickle Cell Awareness Program

14 Sep 2023 07:00:00 By Nasdaq GlobeNewswire

23andMe Granted New FDA Clearance to Report Additional BRCA Variants

31 Aug 2023 17:28:20 By Nasdaq GlobeNewswire

23andMe Reports FY2024 First Quarter Financial Results

08 Aug 2023 16:05:00 By Nasdaq GlobeNewswire

23andMe to Report FY2024 First Quarter Financial Results

25 Jul 2023 16:05:01 By Nasdaq GlobeNewswire

23andMe Releases New FDA-Cleared Genetic Report on Simvastatin, a Commonly Prescribed Statin

20 Jul 2023 09:23:45 By Nasdaq GlobeNewswire

23andMe Releases New Report Revealing Genetic Likelihood of Experiencing Panic Attacks

21 Jun 2023 07:00:00 By Nasdaq GlobeNewswire

23andMe Reports FY2023 Fourth Quarter and Full Year Financial Results

25 May 2023 16:05:00 By Nasdaq GlobeNewswire

New 23andMe survey reveals nine out of ten physicians in the U.S. believe genetics play an important part of a patient’s complete health picture

16 May 2023 07:00:01 By Nasdaq GlobeNewswire

23andMe to Report FY2023 Fourth Quarter and Full Year Financial Results

11 May 2023 16:05:01 By Nasdaq GlobeNewswire

23andMe Releases New Report Revealing Likelihood of Developing Lupus

09 May 2023 07:00:01 By Nasdaq GlobeNewswire

Reza Afkhami Joins 23andMe as Chief Corporate Development Officer

08 May 2023 07:00:00 By Nasdaq GlobeNewswire

23andMe Announces Phase 1 Results from the First-in-Human Phase 1/2a Study of 23ME-00610, an Investigational Antibody Targeting CD200R1

14 Apr 2023 16:05:00 By Nasdaq GlobeNewswire

Morehouse School of Medicine, Sickle Cell Foundation of Georgia and 23andMe Launch Sickle Cell Carrier Status Awareness Program

11 Apr 2023 07:00:00 By Nasdaq GlobeNewswire

23andMe Aims To Raise Awareness of Lipoprotein(a), a Little-Known Genetic Risk Factor for Cardiovascular Disease

24 Mar 2023 07:00:00 By Nasdaq GlobeNewswire

23andMe Announces Presentation of Phase 1 Clinical Data for 23ME-00610, an Investigational Antibody Targeting CD200R1, at the American Association for Cancer Research (AACR) Annual Meeting 2023

14 Mar 2023 16:30:00 By Nasdaq GlobeNewswire

New 23andMe Surveys Find Most People and Doctors Agree that Genetic Testing Offers Promise for More Personalized Healthcare

09 Mar 2023 09:00:00 By Nasdaq GlobeNewswire

23andMe to Present at Upcoming Investor Conferences

22 Feb 2023 16:05:01 By Nasdaq GlobeNewswire

23andMe Reports FY2023 Third Quarter Financial Results

08 Feb 2023 16:05:01 By Nasdaq GlobeNewswire

23andMe to Report FY2023 Third Quarter Financial Results

26 Jan 2023 16:05:00 By Nasdaq GlobeNewswire